Unknown

Dataset Information

0

Discovery of a selective NaV1.7 inhibitor from centipede venom with analgesic efficacy exceeding morphine in rodent pain models.


ABSTRACT: Loss-of-function mutations in the human voltage-gated sodium channel NaV1.7 result in a congenital indifference to pain. Selective inhibitors of NaV1.7 are therefore likely to be powerful analgesics for treating a broad range of pain conditions. Herein we describe the identification of µ-SLPTX-Ssm6a, a unique 46-residue peptide from centipede venom that potently inhibits NaV1.7 with an IC50 of ?25 nM. µ-SLPTX-Ssm6a has more than 150-fold selectivity for NaV1.7 over all other human NaV subtypes, with the exception of NaV1.2, for which the selectivity is 32-fold. µ-SLPTX-Ssm6a contains three disulfide bonds with a unique connectivity pattern, and it has no significant sequence homology with any previously characterized peptide or protein. µ-SLPTX-Ssm6a proved to be a more potent analgesic than morphine in a rodent model of chemical-induced pain, and it was equipotent with morphine in rodent models of thermal and acid-induced pain. This study establishes µ-SPTX-Ssm6a as a promising lead molecule for the development of novel analgesics targeting NaV1.7, which might be suitable for treating a wide range of human pain pathologies.

SUBMITTER: Yang S 

PROVIDER: S-EPMC3808613 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Discovery of a selective NaV1.7 inhibitor from centipede venom with analgesic efficacy exceeding morphine in rodent pain models.

Yang Shilong S   Xiao Yao Y   Kang Di D   Liu Jie J   Li Yuan Y   Undheim Eivind A B EA   Klint Julie K JK   Rong Mingqiang M   Lai Ren R   King Glenn F GF  

Proceedings of the National Academy of Sciences of the United States of America 20130930 43


Loss-of-function mutations in the human voltage-gated sodium channel NaV1.7 result in a congenital indifference to pain. Selective inhibitors of NaV1.7 are therefore likely to be powerful analgesics for treating a broad range of pain conditions. Herein we describe the identification of µ-SLPTX-Ssm6a, a unique 46-residue peptide from centipede venom that potently inhibits NaV1.7 with an IC50 of ∼25 nM. µ-SLPTX-Ssm6a has more than 150-fold selectivity for NaV1.7 over all other human NaV subtypes,  ...[more]

Similar Datasets

| S-EPMC4789675 | biostudies-literature
| S-EPMC5848165 | biostudies-literature
| S-EPMC9983021 | biostudies-literature
| S-EPMC9223482 | biostudies-literature
| S-EPMC7808416 | biostudies-literature
| S-EPMC7232367 | biostudies-literature
| S-EPMC5206724 | biostudies-literature
| S-EPMC4810223 | biostudies-literature
| S-EPMC7471454 | biostudies-literature
| S-EPMC5933747 | biostudies-literature